# Are Cerebrospinal Fluid Biomarkers Useful for the Diagnosis of Cognitive Disorders in Older Patients? A 10-Year Retrospective Study in a Geriatric Memory Clinic at Lille University Medical Center (Lille, France)

Dominique Huvent-Grelle, Yaohua Chen, Claire Vaudreuil, Susanna Schraen, Jean-Baptiste Beuscart, Eric Boulanger, Francois Puisieux

► To cite this version:

Dominique Huvent-Grelle, Yaohua Chen, Claire Vaudreuil, Susanna Schraen, Jean-Baptiste Beuscart, et al.. Are Cerebrospinal Fluid Biomarkers Useful for the Diagnosis of Cognitive Disorders in Older Patients? A 10-Year Retrospective Study in a Geriatric Memory Clinic at Lille University Medical Center (Lille, France). HSOA journal of gerontology & geriatric medicine, 2022, Journal of Gerontology and Geriatric Medicine, 8, pp.146. 10.24966/GGM-8662/100146. hal-04582492

HAL Id: hal-04582492

https://hal.univ-lille.fr/hal-04582492

Submitted on 23 May 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
## Brief report

# Are Cerebrospinal Fluid Biomarkers Useful for the Diagnosis of Cognitive Disorders in Older Patients? A 10-Year Retrospective Study in a Geriatric Memory Clinic at Lille University Medical Center (Lille, France)

Dominique Huvent-Grelle<fnref n="1" />*, Yaohua Chen<fnref n="1" />, Claire Vaudreuil<fnref n="1" />, Susanna Schraen<fnref n="2" />, Jean Baptiste Beuscart<fnref n="1" />, Eric Boulanger<fnref n="1" /> and François Puisieux<fnref n="1" />

## Abstract

We focused on the diagnostic value of Cerebrospinal Fluid (CSF) biomarker assays in older patients. Literature data on this topic are very scarce. CSF biomarkers now constitute an additional body of evidence in the diagnosis of Alzheimer Disease, along with clinical observations, neuropsychological data and imaging findings. We present data obtained in a geriatric memory clinic (Lille, France) over 10 years. We included solely patients having undergone Lumbar Puncture (LP) with diagnostic intent, i.e., when the clinical, neuropsychological and imaging data had not enabled the clinic's physicians to establish a certain diagnosis. A total of 3,236 patients attended our memory clinics; 37 of them underwent LP. The application of CSF biomarker assays enabled rectification of the clinical diagnosis in 35.1% of cases. The diagnosis of cognitive disorders must always be based on a personalized approach.

**Keywords:** Cerebrospinal fluid biomarkers; Cognitive disorders; Lumbar puncture; Older patient

*Corresponding author: Dominique Huvent-Grelle, Pôle de Gérontologie, CHU LILLE, France, E-mail: dominique.huvent@chru-lille.fr

**Citation:** Huvent-Grelle D, Chen Y, Vaudreuil C, Schraen S, Beuscart JB, et al. (2022) Are Cerebrospinal Fluid Biomarkers Useful for the Diagnosis of Cognitive Disorders in Older Patients? A 10-Year Retrospective Study in a Geriatric Memory Clinic at Lille University Medical Center (Lille, France). J Gerontol Geriatr Med 8: 146.

**Received:** September 06, 2022; **Accepted:** September 27, 2022; **Published:** October 04, 2022

**Copyright:** © 2022 Huvent-Grelle D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Introduction

Twenty years ago, research on biomarkers in Alzheimer's Disease (AD) was initiated by the publication of guidelines from the International Working Group and the National Institute on Aging - Alzheimer's Association [1,2]. Cerebrospinal Fluid (CSF) biomarkers now constitute an additional body of evidence in the diagnosis of AD, along with clinical observations, neuropsychological data and imaging findings. CSF biomarkers enable AD to be diagnosed 20 to 30 years before clinical signs appear and also facilitate differential diagnoses with regard to other neurodegenerative or cerebrovascular diseases [3]. This technique is approved in France for the diagnosis of young adults, atypical forms of AD or rapidly progressing cognitive disorders. At present, three markers are assayed: total tau, phosphorylated tau and beta-amyloid peptide. Although the incidence of dementia rises markedly with age, few real-life data on the value of CSF biomarkers in very older people are available [4]. Here, we present data obtained in a geriatric memory clinic at Lille University Medical Center (Lille, France) over 10 years.

## Methodology

We analyzed the data on patients having undergone Lumbar Puncture (LP) in our memory clinic over a 10-year period (2010 to 2019). In fact, we included solely patients having undergone LP with diagnostic intent, i.e., when the clinical, neuropsychological and imaging data had not enabled the clinic's physicians to establish a certain diagnosis. Patients with certain diagnoses in the absence of CSF assays, patients having refused LP, and patients on anticoagulants or with a severe rheumatic disease (making LP impossible, even when guided by a radiologist) were not evaluated. Each patient's hemostatic profile was checked before LP. All patients gave their written, informed consent to the procedure.

## Results

Over the study period, a total of 3,236 patients (mean age: 83) attended our memory clinics; 37 of them underwent LP. In 13 (1/3) of these 37 cases, there was a mismatch between the initial clinical diagnosis and the results of the CSF biomarker assays. The diagnosis has been rectified for these patients (Table 1).

<table><thead><tr><th>Characteristic</th><th>N= 37</th><th>N</th><th>%</th></tr></thead><tbody><tr><td rowspan="2">Sex</td><td>Females</td><td>23</td><td>62.2</td></tr><tr><td>Males</td><td>14</td><td>37.8</td></tr><tr><td rowspan="2">Age (years, mean (SD))</td><td>Females</td><td>76 (8.13)</td><td></td></tr><tr><td>Males</td><td>74 (8.51)</td><td></td></tr><tr><td rowspan="2">Place of residence</td><td>Own home</td><td>34</td><td>91.9</td></tr><tr><td>Nursing/care home</td><td>3</td><td>8.1</td></tr><tr><td>Cardiovascular risk factor</td><td>YES</td><td>29</td><td>78.4</td></tr><tr><td>Antiplatelet agents</td><td>YES</td><td>15</td><td>40.5</td></tr><tr><td rowspan="3">Imaging</td><td>MRI</td><td>36</td><td>97.3</td></tr><tr><td>PET</td><td>6</td><td>16.2</td></tr><tr><td>CT</td><td>1</td><td></td></tr></tbody></table>

<footnote n="1">¹Pôle de Gérontologie, CHU LILLE, France</footnote>

<footnote n="2">²Pôle de Biologie Pathologie Génétique, CHU LILLE, France</footnote>
## Brief report

# Are Cerebrospinal Fluid Biomarkers Useful for the Diagnosis of Cognitive Disorders in Older Patients? A 10-Year Retrospective Study in a Geriatric Memory Clinic at Lille University Medical Center (Lille, France)

Dominique Huvent-Grelle<fnref n="1" />*, Yaohua Chen<fnref n="1" />, Claire Vaudreuil<fnref n="1" />, Susanna Schraen<fnref n="2" />, Jean Baptiste Beuscart<fnref n="1" />, Eric Boulanger<fnref n="1" /> and François Puisieux<fnref n="1" />

## Abstract

We focused on the diagnostic value of Cerebrospinal Fluid (CSF) biomarker assays in older patients. Literature data on this topic are very scarce. CSF biomarkers now constitute an additional body of evidence in the diagnosis of Alzheimer Disease, along with clinical observations, neuropsychological data and imaging findings. We present data obtained in a geriatric memory clinic (Lille, France) over 10 years. We included solely patients having undergone Lumbar Puncture (LP) with diagnostic intent, i.e., when the clinical, neuropsychological and imaging data had not enabled the clinic's physicians to establish a certain diagnosis. A total of 3,236 patients attended our memory clinics; 37 of them underwent LP. The application of CSF biomarker assays enabled rectification of the clinical diagnosis in 35.1% of cases. The diagnosis of cognitive disorders must always be based on a personalized approach.

**Keywords:** Cerebrospinal fluid biomarkers; Cognitive disorders; Lumbar puncture; Older patient

## Introduction

Twenty years ago, research on biomarkers in Alzheimer's Disease (AD) was initiated by the publication of guidelines from the International Working Group and the National Institute on Aging - Alzheimer's Association [1,2]. Cerebrospinal Fluid (CSF) biomarkers now constitute an additional body of evidence in the diagnosis of AD, along with clinical observations, neuropsychological data and imaging findings. CSF biomarkers enable AD to be diagnosed 20 to 30 years before clinical signs appear and also facilitate differential diagnoses with regard to other neurodegenerative or cerebrovascular diseases [3]. This technique is approved in France for the diagnosis of young adults, atypical forms of AD or rapidly progressing cognitive disorders. At present, three markers are assayed: total tau, phosphorylated tau and beta-amyloid peptide. Although the incidence of dementia rises markedly with age, few real-life data on the value of CSF biomarkers in very older people are available [4]. Here, we present data obtained in a geriatric memory clinic at Lille University Medical Center (Lille, France) over 10 years.

## Methodology

We analyzed the data on patients having undergone Lumbar Puncture (LP) in our memory clinic over a 10-year period (2010 to 2019). In fact, we included solely patients having undergone LP with diagnostic intent, i.e., when the clinical, neuropsychological and imaging data had not enabled the clinic's physicians to establish a certain diagnosis. Patients with certain diagnoses in the absence of CSF assays, patients having refused LP, and patients on anticoagulants or with a severe rheumatic disease (making LP impossible, even when guided by a radiologist) were not evaluated. Each patient's hemostatic profile was checked before LP. All patients gave their written, informed consent to the procedure.

## Results

Over the study period, a total of 3,236 patients (mean age: 83) attended our memory clinics; 37 of them underwent LP. In 13 (1/3) of these 37 cases, there was a mismatch between the initial clinical diagnosis and the results of the CSF biomarker assays. The diagnosis has been rectified for these patients (Table 1).

<table><thead><tr><th>Characteristic</th><th>N= 37</th><th>N</th><th>%</th></tr></thead><tbody><tr><td rowspan="2">Sex</td><td>Females</td><td>23</td><td>62.2</td></tr><tr><td>Males</td><td>14</td><td>37.8</td></tr><tr><td rowspan="2">Age (years, mean (SD))</td><td>Females</td><td>76 (8.13)</td><td></td></tr><tr><td>Males</td><td>74 (8.51)</td><td></td></tr><tr><td rowspan="2">Place of residence</td><td>Own home</td><td>34</td><td>91.9</td></tr><tr><td>Nursing/care home</td><td>3</td><td>8.1</td></tr><tr><td>Cardiovascular risk factor</td><td>YES</td><td>29</td><td>78.4</td></tr><tr><td>Antiplatelet agents</td><td>YES</td><td>15</td><td>40.5</td></tr><tr><td rowspan="3">Imaging</td><td>MRI</td><td>36</td><td>97.3</td></tr><tr><td>PET</td><td>6</td><td>16.2</td></tr><tr><td>CT</td><td>1</td><td></td></tr></tbody></table>

<footnote n="1">¹Pôle de Gérontologie, CHU LILLE, France</footnote>

<footnote n="2">²Pôle de Biologie Pathologie Génétique, CHU LILLE, France</footnote>

<footnote>*Corresponding author: Dominique Huvent-Grelle, Pôle de Gérontologie, CHU LILLE, France, E-mail: dominique.huvent@chru-lille.fr</footnote>

<footnote>Citation: Huvent-Grelle D, Chen Y, Vaudreuil C, Schraen S, Beuscart JB, et al. (2022) Are Cerebrospinal Fluid Biomarkers Useful for the Diagnosis of Cognitive Disorders in Older Patients? A 10-Year Retrospective Study in a Geriatric Memory Clinic at Lille University Medical Center (Lille, France). J Gerontol Geriatr Med 8: 146.</footnote>

<footnote>Received: September 06, 2022; Accepted: September 27, 2022; Published: October 04, 2022</footnote>

<footnote>Copyright: © 2022 Huvent-Grelle D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</footnote>
<table><caption>Table 1: Characteristics of the study population.</caption><tr><td>MMSE score out of 30</td><td>Mean (SD)</td><td>26 (2.38)</td><td></td></tr><tr><td>Mattis Dementia Rating<br>Scale score out of 144</td><td>Mean (SD)</td><td>130 (10.41)</td><td></td></tr><tr><td rowspan="4">Diagnosis before the LP</td><td>SCI</td><td>1</td><td rowspan="4">67.5<br>27</td></tr><tr><td>MCI<sup>1</sup></td><td>25</td></tr><tr><td>AD<sup>2</sup></td><td>10</td></tr><tr><td>FTD<sup>3</sup></td><td>1</td></tr><tr><td rowspan="5">Diagnosis after the LP</td><td>SCI</td><td>1</td><td rowspan="5">59.4<br>29.8</td></tr><tr><td>MCI</td><td>22</td></tr><tr><td>AD</td><td>11</td></tr><tr><td>FTD</td><td>1</td></tr><tr><td>LATE<sup>4</sup></td><td>1</td></tr><tr><td>Complication post LP</td><td></td><td>0</td><td></td></tr><tr><td>Diagnosis rectified for 13<br>patients (35.1%)</td><td colspan="3">6 diagnoses of MCI<br>were changed to AD.<br>5 diagnoses of AD<br>were changed to MCI.<br>1 diagnosis of AD was<br>changed to LATE.<br>1 diagnosis of PSP,<br>based on the neuro-<br>logical, imaging and<br>biomarker findings.</td></tr></table>

SCI: Subjective Cognitive Impairment - MCI: Mild Cognitive Impairment-AD: Alzheimer's Disease- FTD: Frontotemporal Dementia - LATE: Limbic-Predominant age-related TDP-43 Encephalopathy - PSP: Progressive Supranuclear Palsy

¹Petersen, 2006

²NIA/AA 2011

³McKhann 2011

⁴Nelson, 2019

## Discussion

According to the participants in the National Institutes of Health workshop in 1998, “the ideal biomarker should be reliable, predictive, unique, reproducible, repeatable and strictly related to the pathological process” [5]. The diagnostic use of CSF biomarkers is subject to various difficulties and limitations. Some sources of assay variability are linked to technical factors (the type of tubes used and the sample collection, transport and storage procedures), the absence of assay standardization, and the lack of internationally agreed cut-off values [3]. In the present analysis, our patients were not extremely old, were living at home and had a high mean Mini Mental State Examination score (Table 1); this is in line with the literature data [3,6,7]. It should also be borne that amyloid disease biomarkers are present in 30% of “cognitively normal” older adults [7]. Other factors must not be forgotten, such as visual disorders, presbycusis and polypharmacy [6].

There are many arguments in favor of the use of biomarker assays in older patients. In our study (as in the literature), we did not encounter any complicating factors [3,6]. The more widespread diagnostic use of this technique might enable the formation of homogeneous

populations (e.g. the A/T/N classification) [2]. It must be also emphasized that dementia is not always linked to amyloid or tau pathology, and the latter diseases can also coexist with cerebrovascular pathologies and hippocampal sclerosis [6]. Matsson et al., have shown that biomarker levels do not vary with age [8], and Herruka et al., have graded recommendations for the conversion of mild cognitive impairment to AD as a function of the levels of three biomarkers [9]. Mouton-Liger et al., reported a mismatch between the initial clinical diagnosis and the LP results in a third of cases; in 77% of these mismatches, the clinician changed his/her initial diagnosis to coincide with the biochemical findings [10]. In the present study, the application of CSF biomarker assays enabled rectification of the clinical diagnosis in 35.1% of cases (Table 1).

## Conclusion

The diagnosis of cognitive disorders must always be based on a personalized approach. The use of data on CSF biomarkers can complement and improve a “composite diagnosis” formed after a clinical examination, a neuropsychological assessment and imaging. These assays enable the accurate differential diagnosis of various types of dementia. The development of less invasive blood biomarker assays would be of assistance to the clinician and would also increase the currently low level of enrollment of older patients in AD clinical trials.

## Financial Disclosure

This research did not receive any specific funding from agencies or organizations in the public, commercial, or not-for-profit sectors.

## Sponsor's Role

The sponsor was not involved in the study design, methods, subject recruitment, data collection, analysis and preparation of the paper.

## Conflict of Interest

None of the authors have any financial conflicts of interest to disclose. This study was designed and conducted in accordance with the tenets of the Declaration of Helsinki.

## Author Contributions

Dominique Huvent-Grelle conceived and designed the study. Susanna Schraen supervised the analysis of the samples. Dominique Huvent-Grelle, Yaohua Chen and Claire Vaudreuil drafted the manuscript. Eric Boulanger and Jean-Baptiste Beuscart searched the literature. François Puisieux revised the manuscript. All authors contributed to the interpretation of the results and approved the final version to be published.

## Acknowledgment

The authors thank Géry Huvent for his invaluable assistance.

## References

1. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, et al. (2014) Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol 13: 614-629.

2. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, et al. (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement 14: 535-562.
<table><caption>Table 1: Characteristics of the study population.</caption><tr><td>MMSE score out of 30</td><td>Mean (SD)</td><td>26 (2.38)</td><td></td></tr><tr><td>Mattis Dementia Rating Scale score out of 144</td><td>Mean (SD)</td><td>130 (10.41)</td><td></td></tr><tr><td rowspan="4">Diagnosis before the LP</td><td>SCI</td><td>1</td><td rowspan="4">67.5<br>27</td></tr><tr><td>MCI<sup>1</sup></td><td>25</td></tr><tr><td>AD<sup>2</sup></td><td>10</td></tr><tr><td>FTD<sup>3</sup></td><td>1</td></tr><tr><td rowspan="5">Diagnosis after the LP</td><td>SCI</td><td>1</td><td rowspan="5">59.4<br>29.8</td></tr><tr><td>MCI</td><td>22</td></tr><tr><td>AD</td><td>11</td></tr><tr><td>FTD</td><td>1</td></tr><tr><td>LATE<sup>4</sup></td><td>1</td></tr><tr><td>Complication post LP</td><td></td><td>0</td><td></td></tr><tr><td>Diagnosis rectified for 13 patients (35.1%)</td><td colspan="3">6 diagnoses of MCI were changed to AD. 5 diagnoses of AD were changed to MCI. 1 diagnosis of AD was changed to LATE. 1 diagnosis of PSP, based on the neurological, imaging and biomarker findings.</td></tr></table>

SCI: Subjective Cognitive Impairment - MCI: Mild Cognitive Impairment- AD: Alzheimer's Disease- FTD: Frontotemporal Dementia - LATE: Limbic-Predominant age-related TDP-43 Encephalopathy - PSP: Progressive Supranuclear Palsy

¹Petersen, 2006

²NIA/AA 2011

³McKhann 2011

⁴Nelson, 2019

## Discussion

According to the participants in the National Institutes of Health workshop in 1998, “the ideal biomarker should be reliable, predictive, unique, reproducible, repeatable and strictly related to the pathological process” [5]. The diagnostic use of CSF biomarkers is subject to various difficulties and limitations. Some sources of assay variability are linked to technical factors (the type of tubes used and the sample collection, transport and storage procedures), the absence of assay standardization, and the lack of internationally agreed cut-off values [3]. In the present analysis, our patients were not extremely old, were living at home and had a high mean Mini Mental State Examination score (Table 1); this is in line with the literature data [3,6,7]. It should also be borne that amyloid disease biomarkers are present in 30% of “cognitively normal” older adults [7]. Other factors must not be forgotten, such as visual disorders, presbycusis and polypharmacy [6].

There are many arguments in favor of the use of biomarker assays in older patients. In our study (as in the literature), we did not encounter any complicating factors [3,6]. The more widespread diagnostic use of this technique might enable the formation of homogeneous

populations (e.g. the A/T/N classification) [2]. It must be also emphasized that dementia is not always linked to amyloid or tau pathology, and the latter diseases can also coexist with cerebrovascular pathologies and hippocampal sclerosis [6]. Matsson et al., have shown that biomarker levels do not vary with age [8], and Herruka et al., have graded recommendations for the conversion of mild cognitive impairment to AD as a function of the levels of three biomarkers [9]. Mouton-Liger et al., reported a mismatch between the initial clinical diagnosis and the LP results in a third of cases; in 77% of these mismatches, the clinician changed his/her initial diagnosis to coincide with the biochemical findings [10]. In the present study, the application of CSF biomarker assays enabled rectification of the clinical diagnosis in 35.1% of cases (Table 1).

## Conclusion

The diagnosis of cognitive disorders must always be based on a personalized approach. The use of data on CSF biomarkers can complement and improve a “composite diagnosis” formed after a clinical examination, a neuropsychological assessment and imaging. These assays enable the accurate differential diagnosis of various types of dementia. The development of less invasive blood biomarker assays would be of assistance to the clinician and would also increase the currently low level of enrollment of older patients in AD clinical trials.

## Financial Disclosure

This research did not receive any specific funding from agencies or organizations in the public, commercial, or not-for-profit sectors.

## Sponsor's Role

The sponsor was not involved in the study design, methods, subject recruitment, data collection, analysis and preparation of the paper.

## Conflict of Interest

None of the authors have any financial conflicts of interest to disclose. This study was designed and conducted in accordance with the tenets of the Declaration of Helsinki.

## Author Contributions

Dominique Huvent-Grelle conceived and designed the study. Susanna Schraen supervised the analysis of the samples. Dominique Huvent-Grelle, Yaohua Chen and Claire Vaudreuil drafted the manuscript. Eric Boulanger and Jean-Baptiste Beuscart searched the literature. François Puisieux revised the manuscript. All authors contributed to the interpretation of the results and approved the final version to be published.

## Acknowledgment

The authors thank Géry Huvent for his invaluable assistance.

## References

1. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, et al. (2014) Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol 13: 614-629.

2. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, et al. (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement 14: 535-562.
3. Sonnen JA, Montine KS, Quinn JF, Kaye JA, Breitner JC, et al. (2008) Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol 7: 704-714.

4. Alzheimer's Disease International (ADI) (2019). World Alzheimer Report 2018. ADI, London, UK.

5. NIH Workshop (1998) Research needs for the Design and Analysis of Surrogate Endpoints in Clinical Trials. NIH Workshop.

6. Paolacci L, Giannandrea D, Mecocci P, Parnetti L (2017) Biomarkers for Early Diagnosis of Alzheimer's Disease in the Oldest Old: Yes or No? J Alzheimers Dis 58: 323-335.

7. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, et al. (2015) Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA 313: 1924-1938.

8. Mattsson N, Rosén E, Hansson O, Andreasen N, Parnetti L, et al. (2012) Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 78: 468-476.

9. Herukka SK, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, et al. (2017) Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimers Dement 13: 285-295.

10. Mouton-Liger F, Wallon D, Troussière AC, Yatimi R, Dumurgier J, et al. (2014) Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: A multicentric study. J Neurol 261: 144-151.
3. Sonnen JA, Montine KS, Quinn JF, Kaye JA, Breitner JC, et al. (2008) Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol 7: 704-714.

4. Alzheimer's Disease International (ADI) (2019). World Alzheimer Report 2018. ADI, London, UK.

5. NIH Workshop (1998) Research needs for the Design and Analysis of Surrogate Endpoints in Clinical Trials. NIH Workshop.

6. Paolacci L, Giannandrea D, Mecocci P, Parnetti L (2017) Biomarkers for Early Diagnosis of Alzheimer's Disease in the Oldest Old: Yes or No? J Alzheimers Dis 58: 323-335.

7. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, et al. (2015) Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA 313: 1924-1938.

8. Mattsson N, Rosén E, Hansson O, Andreasen N, Parnetti L, et al. (2012) Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 78: 468-476.

9. Herukka SK, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, et al. (2017) Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimers Dement 13: 285-295.

10. Mouton-Liger F, Wallon D, Troussière AC, Yatimi R, Dumurgier J, et al. (2014) Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: A multicentric study. J Neurol 261: 144-151.
<figure><img src="image_1.png" /></figure>

Advances In Industrial Biotechnology | ISSN: 2639-5665

Advances In Microbiology Research | ISSN: 2689-694X

Archives Of Surgery And Surgical Education | ISSN: 2689-3126

Archives Of Urology

Archives Of Zoological Studies | ISSN: 2640-7779

Current Trends Medical And Biological Engineering

International Journal Of Case Reports And Therapeutic Studies | ISSN: 2689-310X

Journal Of Addiction & Addictive Disorders | ISSN: 2578-7276

Journal Of Agronomy & Agricultural Science | ISSN: 2689-8292

Journal Of AIDS Clinical Research & STDs | ISSN: 2572-7370

Journal Of Alcoholism Drug Abuse & Substance Dependence | ISSN: 2572-9594

Journal Of Allergy Disorders & Therapy | ISSN: 2470-749X

Journal Of Alternative Complementary & Integrative Medicine | ISSN: 2470-7562

Journal Of Alzheimers & Neurodegenerative Diseases | ISSN: 2572-9608

Journal Of Anesthesia & Clinical Care | ISSN: 2378-8879

Journal Of Angiology & Vascular Surgery | ISSN: 2572-7397

Journal Of Animal Research & Veterinary Science | ISSN: 2639-3751

Journal Of Aquaculture & Fisheries | ISSN: 2576-5523

Journal Of Atmospheric & Earth Sciences | ISSN: 2689-8780

Journal Of Biotech Research & Biochemistry

Journal Of Brain & Neuroscience Research

Journal Of Cancer Biology & Treatment | ISSN: 2470-7546

Journal Of Cardiology Study & Research | ISSN: 2640-768X

Journal Of Cell Biology & Cell Metabolism | ISSN: 2381-1943

Journal Of Clinical Dermatology & Therapy | ISSN: 2378-8771

Journal Of Clinical Immunology & Immunotherapy | ISSN: 2378-8844

Journal Of Clinical Studies & Medical Case Reports | ISSN: 2378-8801

Journal Of Community Medicine & Public Health Care | ISSN: 2381-1978

Journal Of Cytology & Tissue Biology | ISSN: 2378-9107

Journal Of Dairy Research & Technology | ISSN: 2688-9315

Journal Of Dentistry Oral Health & Cosmesis | ISSN: 2473-6783

Journal Of Diabetes & Metabolic Disorders | ISSN: 2381-201X

Journal Of Emergency Medicine Trauma & Surgical Care | ISSN: 2378-8798

Journal Of Environmental Science Current Research | ISSN: 2643-5020

Journal Of Food Science & Nutrition | ISSN: 2470-1076

Journal Of Forensic Legal & Investigative Sciences | ISSN: 2473-733X

Journal Of Gastroenterology & Hepatology Research | ISSN: 2574-2566

Journal Of Genetics & Genomic Sciences | ISSN: 2574-2485

Journal Of Gerontology & Geriatric Medicine | ISSN: 2381-8662

Journal Of Hematology Blood Transfusion & Disorders | ISSN: 2572-2999

Journal Of Hospice & Palliative Medical Care

Journal Of Human Endocrinology | ISSN: 2572-9640

Journal Of Infectious & Non Infectious Diseases | ISSN: 2381-8654

Journal Of Internal Medicine & Primary Healthcare | ISSN: 2574-2493

Journal Of Light & Laser Current Trends

Journal Of Medicine Study & Research | ISSN: 2639-5657

Journal Of Modern Chemical Sciences

Journal Of Nanotechnology Nanomedicine & Nanobiotechnology | ISSN: 2381-2044

Journal Of Neonatology & Clinical Pediatrics | ISSN: 2378-878X

Journal Of Nephrology & Renal Therapy | ISSN: 2473-7313

Journal Of Non Invasive Vascular Investigation | ISSN: 2572-7400

Journal Of Nuclear Medicine Radiology & Radiation Therapy | ISSN: 2572-7419

Journal Of Obesity & Weight Loss | ISSN: 2473-7372

Journal Of Ophthalmology & Clinical Research | ISSN: 2378-8887

Journal Of Orthopedic Research & Physiotherapy | ISSN: 2381-2052

Journal Of Otolaryngology Head & Neck Surgery | ISSN: 2573-010X

Journal Of Pathology Clinical & Medical Research

Journal Of Pharmacology Pharmaceutics & Pharmacovigilance | ISSN: 2639-5649

Journal Of Physical Medicine Rehabilitation & Disabilities | ISSN: 2381-8670

Journal Of Plant Science Current Research | ISSN: 2639-3743

Journal Of Practical & Professional Nursing | ISSN: 2639-5681

Journal Of Protein Research & Bioinformatics

Journal Of Psychiatry Depression & Anxiety | ISSN: 2573-0150

Journal Of Pulmonary Medicine & Respiratory Research | ISSN: 2573-0177

Journal Of Reproductive Medicine Gynaecology & Obstetrics | ISSN: 2574-2574

Journal Of Stem Cells Research Development & Therapy | ISSN: 2381-2060

Journal Of Surgery Current Trends & Innovations | ISSN: 2578-7284

Journal Of Toxicology Current Research | ISSN: 2639-3735

Journal Of Translational Science And Research

Journal Of Vaccines Research & Vaccination | ISSN: 2573-0193

Journal Of Virology & Antivirals

Sports Medicine And Injury Care Journal | ISSN: 2689-8829

Trends In Anatomy & Physiology | ISSN: 2640-7752

Submit Your Manuscript: https://www.heraldopenaccess.us/submit-manuscript